Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells.
antigens
epitope
eplets
flow cytometry
hematopoietic cell transplantation
single antigen bead
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
19 Aug 2023
19 Aug 2023
Historique:
revised:
30
06
2023
received:
12
12
2022
accepted:
31
07
2023
medline:
19
8
2023
pubmed:
19
8
2023
entrez:
19
8
2023
Statut:
aheadofprint
Résumé
HLA Class I and II expression are known to differ locus-to-locus, however, HLA expression on the cell-surface is frequently reported as the total amount of HLA Class I or II antigens. This is despite evidence that indicates the differential expression of HLA can influence patient outcomes post-transplantation. Although numerous commercially available HLA monoclonal antibodies (mAbs) exist to characterize HLA expression, there is currently a lack of detailed information regarding their reactivities to HLA specificities. The specificities of locus-specific HLA mAbs (nine Class I and four Class II mAbs) were evaluated by two solid-phase Luminex single antigen bead assays. The reactivity patterns of these mAbs were then confirmed by flow cytometry using lymphocytes and PBSCs (peripheral blood stem cells). Out of the 13 HLA mAbs tested, only four (one Class I and three Class II mAbs) displayed intra-locus reactivity without also reacting to inter-locus specificities. Epitope analysis revealed the presence of shared epitopes across numerous HLA loci, explaining much of the observed inter-locus reactivity. The specificity of the HLA mAbs seen in solid-phase assays was confirmed against PBSCs and lymphocytes by flow cytometry. Using this method, we observed differences in the cell surface expression of HLA-C, HLA-DR, HLA-DQ, and HLA-DP between PBSCs and lymphocytes. Our results emphasize the need to characterize the reactivity patterns of HLA mAbs using solid-phase assays before their use on cells. Through understanding the reactivity of these HLA mAbs, the cellular expression of HLA can be more accurately assessed in downstream assays.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.
Références
Berah M, Hors J, Dausset J. A study of HL-A antigens in human organs. Transplantation. 1970;9(3):185-192.
Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2015;43(Database issue):D423-D431.
Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54(1):15-39.
Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn. 2001;3(3):98-104.
Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science. 1996;272(5258):67-74.
Focosi D, Zucca A, Scatena F. The role of anti-HLA antibodies in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1585-1588.
Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115(13):2704-2708.
Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant. 2013;13(12):3114-3122.
Zhang X, Wang J, Zhou Z, et al. The role of HLA antibodies in HLA mismatched allogeneic hematopoietic stem cell transplantation. Clin Transpl. 2014:245-250.
Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105(3):369-377.
Saraceni F, Shem-Tov N, Olivieri A, Nagler A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant. 2015;50(7):886-891.
Xu Q, House AA, Leckie S, Gunaratnam L, Luke PP, Jevnikar AM. Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch. Hum Immunol. 2019;80(7):487-492.
Badders JL, Jones JA, Jeresano ME, Schillinger KP, Jackson AM. Variable HLA expression on deceased donor lymphocytes: not all crossmatches are created equal. Hum Immunol. 2015;76(11):795-800.
Hetrick SJ, Schillinger KP, Zachary AA, Jackson AM. Impact of pronase on flow cytometric crossmatch outcome. Hum Immunol. 2011;72(4):330-336.
Yilmaz A, Reiss C, Weng A, et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006;79(3):529-538.
Petersdorf EW, Malkki M, O'HUigin C, et al. High HLA-DP expression and graft-versus-host disease. N Engl J Med. 2015;373(7):599-609.
Petersdorf EW, Gooley TA, Malkki M, et al. HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood. 2014;124(26):3996-4003.
Kennedy PR, Barthen C, Williamson DJ, Davis DM. HLA-B and HLA-C differ in their nanoscale organization at cell surfaces. Front Immunol. 2019;10:61.
Ramsuran V, Naranbhai V, Horowitz A, et al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science. 2018;359(6371):86-90.
Apps R, Qi Y, Carlson JM, et al. Influence of HLA-C expression level on HIV control. Science. 2013;340(6128):87-91.
Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(12):967-972.
Isa A, Nehlin JO, Sabir HJ, et al. Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors. PloS One. 2010;5(5):e10900.
Yarzabek B, Zaitouna AJ, Olson E, et al. Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity. Elife. 2018;7:e34961.
Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, Tonn T. Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD stem cell enumeration kit. Cytotherapy. 2011;13(4):449-458.
Menezes Teles EOD, Santos M, de Serpa BR, et al. pHLA3D: an online database of predicted three-dimensional structures of HLA molecules. Hum Immunol. 2019;80(10):834-841.
Minuti B, Lari A, Iozzi S, et al. Chimerism analysis using next generation sequencing. Forensic Sci Int Genet Suppl Ser. 2019;7(1):152-153.
El-Awar N, Lee JH, Tarsitani C, Terasaki PI. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol. 2007;68(3):170-180.
Duquesnoy RJ, Marrari M, Mulder A, Sousa LC, da Silva AS, do Monte SJ. First report on the antibody verification of HLA-ABC epitopes recorded in the website-based HLA epitope registry. Tissue Antigens. 2014;83(6):391-400.
Battle R, Turner D, Woodroofe N, Clark B. Identified HLA class I epitopes can undergo conformational induced variation due to changes within HLA bound peptides. Immunol Lett. 2014;161(1):57-58.
Zarutskie JA, Sato AK, Rushe MM, et al. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Biochemistry. 1999;38(18):5878-5887.
Visentin J, Marroc M, Guidicelli G, et al. Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation. Clin Transplant. 2015;29(5):393-402.
Otten HG, Verhaar MC, Borst HP, et al. The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol. 2013;173(3):536-543.
Vittoraki AG, Fylaktou A, Tarassi K, et al. Hidden patterns of anti-HLA class I alloreactivity revealed through machine learning. Front Immunol. 2021;12:670956.
Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol. 1998;8(1):1-10.
Moro M, Cecconi V, Martinoli C, et al. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunol. 2005;6:24.
Arimilli S, Cardoso C, Mukku P, Baichwal V, Nag B. Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains. J Biol Chem. 1995;270(2):971-977.
Stockel J, Meinl E, Hahnel C, et al. Refolding of human class II major histocompatibility complex molecules isolated from Escherichia coli. Assembly of peptide-free heterodimers and increased refolding-yield in the presence of antigenic peptide. J Biol Chem. 1994;269(47):29571-29578.
Royston I, Omary MB, Trowbridge IS. Monoclonal antibodies to a human T-cell antigen and Ia-like antigen in the characterization of lymphoid leukemia. Transplant Proc. 1981;13(1 Pt 2):761-766.
Visentin J, Guidicelli G, Moreau JF, Lee JH, Taupin JL. Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation. Eur J Immunol. 2015;45(7):2111-2121.
Nei M, Gu X, Sitnikova T. Evolution by the birth-and-death process in multigene families of the vertebrate immune system. Proc Natl Acad Sci USA. 1997;94(15):7799-7806.
Apps R, Meng Z, del Prete GQ, Lifson JD, Zhou M, Carrington M. Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells. J Immunol. 2015;194(8):3594-3600.
Raghavan M, Yarzabek B, Zaitouna AJ, Krishnakumar S, Ramon DS. Strategies for the measurements of expression levels and half-lives of HLA class I allotypes. Hum Immunol. 2019;80(4):221-227.
Datema G, Stein S, Eijsink C, Mulder A, Claas FHJ, Doxiadis IIN. HLA-C expression on platelets: studies with an HLA-Cw1-specific human monoclonal antibody. Vox Sang. 2000;79(2):108-111.
Bettinotti MP, Lucas DP, Ghiaur G, Jackson AM, Gladstone DE. HLA-class I and II antigens are expressed in CD34+ cells: implications for HLA mismatched bone marrow transplantation (BMT). Biol Blood Marrow Transplant. 2018;24(3):S420-S421.
Bettinotti MP, Lucas DP, Ghiaur G, Jackson AM, Gladstone DE. OR30 HLA expression on CD34+ stem cells: is a flow cytometric crossmatch a good gatekeeper for mismatched hematopoietic cell transplantion? Hum Immunol. 2018;79:79.
Dellgren C, Ekwelum VA, Ormhoj M, et al. Low constitutive cell surface expression of HLA-B is caused by a posttranslational mechanism involving Glu180 and Arg239. J Immunol. 2016;197(12):4807-4816.
Aguiar VRC, Castelli EC, Single RM, et al. Comparison between qPCR and RNA-seq reveals challenges of quantifying HLA expression. Immunogenetics. 2023;1-14:249-262.